Colorectal cancer (CRC) stands as the second most common cause of cancer-related mortality globally and p53, a widely recognized tumor suppressor, contributes to the development of CRC.

Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's internal, ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's internal, ...

This TUNDRA comic was among the humorous images participants viewed in a study that yielded unique findings on the role of ...

Researchers also noticed that the mice used as models for Alzheimer’s disease who were given stool transplants from healthy ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

"Stool-based test offers a promising solution to reduce the burden of a colonoscopy," experts emphasized on September 21st, ...

A team of epidemiologists at the First Hospital of Hebei Medical University, in China, has shown experimental evidence of an ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...